Nestlé announced Tuesday it will divest its Vitamins, Minerals and Supplements business—the so-called Holistic Health portfolio—to an undisclosed private equity firm for approximately $1 billion. The portfolio includes mainstream supplement brands that the company has struggled to differentiate in a market increasingly dominated by direct-to-consumer wellness specialists and clinical-grade formulations.

The transaction marks Nestlé's latest retreat from categories where premium positioning has proven difficult to sustain. The VMS business generated roughly $800 million in annual revenue, placing it at a 1.25x multiple on sales—compressed compared to the 2-3x multiples specialty supplement brands with strong DTC channels command. Management cited strategic refocusing on core nutrition and health science platforms where the company maintains defendable moats. The buyer, unnamed in Tuesday's release, is expected to be a mid-market healthcare-focused PE shop seeking roll-up opportunities in fragmented wellness categories.

This divestiture matters because it exposes the continued erosion of large CPG companies' pricing power in health-adjacent categories. Nestlé bought into VMS through a series of acquisitions in the 2000s, betting it could leverage distribution scale. Instead, the business faced margin compression as Amazon and specialty retailers shifted consumer preference toward targeted formulations and transparent sourcing stories—narratives difficult for conglomerates to credibly tell. The $1 billion price suggests the buyer sees operational upside through cost-out and potential bolt-on acquisitions, not revenue growth from the existing portfolio.

Allocators tracking consumer staples should note this as evidence that even premier operators cannot will margin expansion in categories where brand equity has decoupled from distribution reach. Nestlé's pivot toward medical nutrition and infant formula—higher-regulation, higher-margin segments with clinical validation requirements—leaves less capital for defending share in commoditizing wellness. The PE buyer inherits a business that will require either significant reformulation investment or aggressive SKU rationalization to compete with brands like Ritual, Care/of, and AG1 that own specific demographic cohorts.

The transaction is expected to close in Q2 2025, subject to standard regulatory clearances. Watch for Nestlé to redeploy proceeds into its Health Science division, likely through tuck-in acquisitions in pediatric or senior nutrition where reimbursement pathways create defensible economics. Also monitor whether the buyer surfaces within six months—if it's a known roll-up platform, expect follow-on deals in adjacent supplement categories by year-end.

Nestlé now holds CHF 4.2 billion in cash post-announcement, with no immediate deployment guidance beyond the vague "strategic priorities" language. That dry powder sits while the company's organic growth has decelerated to 2.1% over the trailing twelve months, below the 3-4% it guided for 2025. The market is pricing in either a larger acquisition or accelerated buybacks by mid-year.